Cargando…
Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study
Autores principales: | Nelli, F., Fabbri, A., Onorato, A., Giannarelli, D., Silvestri, M.A., Pessina, G., Giron Berrios, J.R., Virtuoso, A., Marrucci, E., Schirripa, M., Mazzotta, M., Panichi, V., Cercola, P., Signorelli, C., Chilelli, M.G., Primi, F., Ruggeri, E.M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660134/ https://www.ncbi.nlm.nih.gov/pubmed/34896598 http://dx.doi.org/10.1016/j.annonc.2021.12.001 |
Ejemplares similares
-
Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study
por: Ruggeri, E.M., et al.
Publicado: (2021) -
Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study
por: Nelli, F., et al.
Publicado: (2022) -
Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study
por: Nelli, F., et al.
Publicado: (2022) -
Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study
por: Nelli, Fabrizio, et al.
Publicado: (2022) -
Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study
por: Nelli, Fabrizio, et al.
Publicado: (2023)